BioSpace News Archive

Polyphor AG presented yesterday new data from pulmonary delivery of its lead antibacterial candidate of the novel Outer Membrane Protein Targeting Antibiotic class, murepavadin, at the 42nd European Cystic Fibrosis Conference in Liverpool, United Kingdom.

CYROLITE® acrylic-based polymers have been a proven material in medical technology for over 40 years.

Proteomics International meeting with US tier 1 national diagnostic groups to expand global roll-out of PromarkerD including EU and Mexico

With the treatment center at the Paracelsus Clinic in Zwickau another geographically important location will soon offer NanoTherm therapy for brain tumor patients

Global Blood Therapeutics, Inc. announced that on June 1, 2019, the compensation committee of GBT’s board of directors granted 19 new employees options to purchase an aggregate of 35,600 shares of the company’s common stock with a per share exercise price of $60.78 and restricted stock units for an aggregate of 96,700 shares of the company’s common stock.

Analysis of 30-year follow up of more than 500 adults in China examines the extent of increased cardiovascular risk can be attributed to diabetes

TrialNet research indicates immune therapy can slow the progression to disease in people identified as high risk for developing T1D

Five Prime Therapeutics, Inc. announced the departure of Dr. Sheila Gujrathi from the company’s board of directors.

RISE researchers present Adult Medication Study results at the ADA’s Scientific Sessions and share the first direct comparison for youth and adult studies

Acucela Inc., a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., announced that the European Medicines Agency granted orphan designation to Acucela’s leading drug candidate emixustat hydrochloride for the treatment of Stargardt disease.